☆ 4.3 Review

Venetoclax in Acute Myeloid Leukemia

RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition

Bing Z. Carter et al.

Summary: MCL-1 and BCL-2 are both overexpressed in acute myeloid leukemia (AML) and play crucial roles in the survival of AML cells and stem cells. Inhibition of MCL-1 enhances the sensitivity to BCL-2 inhibition and improves the efficacy of treatment. Additionally, MCL-1 regulates cell metabolism and leukemia-stromal interactions, providing new mechanisms for AML development.

HAEMATOLOGICA (2022)

Add to Collection

Article Hematology

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

Raghuveer Singh Mali et al.

Summary: The combination of FLT3-ITD inhibition with venetoclax demonstrates impressive anti-tumor activity in FLT3-ITD+ AML preclinical models, highlighting the strong mechanistic rationale for clinical studies.

HAEMATOLOGICA (2021)

Add to Collection

Article Hematology

Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies

Andrius Zucenka et al.

Summary: This retrospective analysis evaluated the outcomes of 28 heavily pretreated relapsed/refractory acute myeloid leukemia patients who failed salvage venetoclax-based therapies. The overall response rate after post-venetoclax salvage therapies was 23%, with a small proportion of patients responding to cautious intensification of chemotherapy with venetoclax. However, remission rates and survival were found to be poor for patients failing venetoclax therapy.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Hematology

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality

Abhishek Maiti et al.

Summary: Hypomethylating agents with venetoclax have become a new standard for older/unfit patients with AML. Comparisons between HMA with venetoclax and intensive chemotherapy in both fit and unfit patients show that DEC10-VEN therapy offers better outcomes, particularly in those at high-risk of treatment-related mortality.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Esther Schuler et al.

Summary: The retrospective study evaluated the efficacy of Venetoclax combined with hypomethylating agents in treating relapse of myeloid malignancies after alloHSCT. Results showed significant risk of neutropenia and infections, with substantial toxicity. Patients who received the treatment as first salvage therapy or for molecular relapse derived the greatest benefit.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial

Odelia Amit et al.

Summary: In this study, the combination of DLI and venetoclax showed increased response in patients with early relapse of acute myeloid leukemia post allogeneic HCT. The majority of patients were able to tolerate the treatment protocol, and a good overall response and moderate survival period were observed. Cox regression analysis indicated that decreased WBC at relapse, GVHD, and better performance status were associated with better survival outcomes. These results suggest that enhancing alloreactivity combined with venetoclax may be a safe and effective treatment approach for this challenging patient group, warranting further investigation in prospective trials.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Article Oncology

Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach

Sumit Bhatnagar et al.

Summary: The study developed and clinically verified posaconazole PBPK models, and predicted the exposures of venetoclax when co-administered with delayed release tablets of posaconazole. The results showed that the exposures were within the safe range, confirming the venetoclax label recommendation in the presence of posaconazole at doses up to 500 mg QD.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)

Add to Collection

Review Oncology

Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases

Jonathan Feld et al.

Summary: Advancements in the understanding of AML pathogenesis have led to the introduction of novel drugs like glasdegib. Clinical trials are ongoing to evaluate the efficacy of glasdegib in newly diagnosed AML patients, providing hope for improvements in outcomes for this devastating disease.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Article Oncology

Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia

Ashkan Emadi et al.

Summary: The combination therapy of venetoclax and Pegylated Crisantaspase showed synergistic anti-leukemic activity in complex karyotype acute myeloid leukemia, both in vitro and in vivo. This novel approach holds promise as a potential new treatment strategy for this challenging subtype of leukemia.

LEUKEMIA (2021)

Add to Collection

Article Oncology

The propriety of upgrading responses to venetoclax plus azacitidine in newly diagnosed patients with acute myeloid leukemia

Diana Abbott et al.

Summary: Response criteria developed for AML in the context of intensive chemotherapy may underestimate responses in continuously-administered venetoclax-based therapies. Interrupting venetoclax-based therapies after an end-of-cycle bone marrow biopsy showing morphologic remission with cytopenias is recommended. Results suggest consideration of new response criteria for venetoclax-based regimens, as outcomes differ from traditional intensive chemotherapy.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Review Hematology

Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?

Sonal Agarwal et al.

Summary: Venetoclax, an oral BCL-2 inhibitor, has been approved for use in newly-diagnosed AML patients who are ineligible for intensive chemotherapy, showing promising complete remission rates in clinical trials. Further studies are needed to explore its long-term efficacy, compare with intensive chemotherapy in specific patient populations, and investigate novel triplet combinations.

EXPERT REVIEW OF HEMATOLOGY (2021)

Add to Collection

Article Oncology

225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models

Ravendra Garg et al.

Summary: Despite the availability of new drugs, many patients with acute myeloid leukemia (AML) do not achieve remission and outcomes remain poor. Venetoclax is a promising new therapy approved for use in combination with a hypomethylating agent or with low-dose cytarabine for the treatment of newly diagnosed older AML patients or those ineligible for intensive chemotherapy. Actinium-lintuzumab (Ac-225-lintuzumab) is a clinical stage radioimmunotherapy targeting CD33 that has shown evidence of single-agent activity in relapsed/refractory AML. Increased expression of MCL-1 is a mediator of resistance to venetoclax in cancer.

CANCER MEDICINE (2021)

Add to Collection

Letter Oncology

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Sakshi Jasra et al.

Summary: The FDA approval of Ivosidenib and Enasidenib has introduced new possibilities for the treatment of acute myeloid leukemia (AML) in elderly patients. The successful case of a 60-year-old woman achieving complete response to combination therapy with Azacytidine, Enasidenib, and Venetoclax marks a significant advancement in the treatment of refractory AML.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Hematology

Which novel agents will have a clinically meaningful impact in AML at diagnosis?

Alexander E. Perl

Summary: New drug approvals have widened the treatment options for AML physicians, with traditional chemotherapies being gradually replaced by novel agents like biologically targeted drugs. Combinations of novel agents and chemotherapy are likely to provide maximum response and survival benefits in AML therapy, with the potential for some patients to benefit from venetoclax-based regimens.

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy A case report

Lei Wang et al.

Summary: This case report illustrates a patient with chronic lymphocytic leukemia (CLL) who achieved morphological complete remission in both CLL and the subsequent secondary AML after one course of venetoclax monotherapy, demonstrating the potential of targeted therapies in changing the prognosis of hematological malignancies.

MEDICINE (2021)

Add to Collection

Article Oncology

Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells

Angel Y. F. Kam et al.

Summary: The ERBB2 proto-oncogene is associated with an aggressive phenotype in breast cancer, but its role in hematologic malignancies is not fully understood. Truncated ERBB2 is over-expressed in MDS and AML cells, and inhibition of ERBB2 signaling can increase apoptotic cell death. Dual blockade with ERBB2 and BCL2 inhibitors shows synergistic effects and shifts cancer cells to a pro-apoptotic phenotype.

MOLECULAR CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia

Ari Pelcovits et al.

Summary: Our study showed that outpatient ramp up of venetoclax in combination with HMAs for the treatment of AML is safe, with a very low risk of laboratory TLS (2.5%) and no evidence of clinical TLS within our cohort.

SUPPORTIVE CARE IN CANCER (2021)

Add to Collection

Letter Oncology

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Abhishek Maiti et al.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Oncology

Acute myeloid leukemia: current progress and future directions

Hagop Kantarjian et al.

Summary: Advancements in understanding and therapy of AML have been rapid, with targeted therapies such as venetoclax and FLT3 inhibitors being approved for various indications. Expertise is crucial in managing the complexity of AML treatment, tailored to the specific subentities for optimal outcomes.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Review Oncology

Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options

Daniel R. Richardson et al.

Summary: Secondary acute myeloid leukemia (s-AML) is a distinct subgroup of AML with poor outcomes despite recent advances in treatment. Patients with s-AML who have received prior hypomethylating agent (HMA) therapy have limited treatment options and are underrepresented in clinical trials. Novel therapeutic options for this population are critically needed.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)

Add to Collection

Article Oncology

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Matthew E. Tenold et al.

Summary: Relapsed/refractory acute myeloid leukemia (AML) is a challenging disease with poor prognosis. This study reports on treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine in a real-world academic center setting, showing an overall response rate of 52% with promising outcomes for patients achieving complete remission.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Hematology

Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax

Blake S. Moses et al.

Summary: Artemisinins have shown synergy with BCL2 inhibitors in inhibiting leukemia cell growth and inducing apoptosis. The SAV regimen targets MCL1 and BCL2 through tolerable mechanisms, with MCL1 and DDIT3/CHOP levels potentially serving as biomarkers for the action of artemisinins and SAV.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia

Kishan K. Patel et al.

Summary: The combination therapy of azacitidine-venetoclax shows improved survival rates for previously untreated AML patients but is deemed cost-ineffective due to significantly higher healthcare costs. Further reduction in the price of venetoclax is necessary to make it a more cost-effective treatment option.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice

Arie Apel et al.

Summary: Combination therapy of venetoclax with hypomethylating agents or low dose cytarabine has shown promising efficacy and safety in AML patients unfit for intensive therapy. The treatment resulted in high rates of complete remission, with adverse karyotype and ECOG performance status being significant predictors of outcomes. Treatment was generally well-tolerated, with tumor lysis syndrome occurring in a minority of patients.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

Naseema Gangat et al.

Summary: Venetoclax combined with a hypomethylating agent has shown efficacy in treating acute myeloid leukemia, especially in patients with blast-phase myeloproliferative neoplasm. The treatment resulted in high rates of complete remission, particularly in those without RAS mutations and complex karyotype, allowing for potential allogeneic hematopoietic stem cell transplant in some cases.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Rachel Thijssen et al.

Summary: Selective targeting of BCL-2 with BH3-mimetic venetoclax has shown promising results in treating various leukemias. However, for patients with TP53 mutations, a combined BH3-mimetic approach targeting both BCL-2 and MCL-1 proves to be more effective in suppressing leukemia burden. It is crucial to use sufficiently lethal treatment strategies to maximize outcomes for patients with TP53-mutant disease and to avoid the risk of disease progression driven by emergent TP53-mutant clones.

BLOOD (2021)

Add to Collection

Article Hematology

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia

Xiaojia Niu et al.

Summary: The study demonstrates that inhibiting the AXL pathway in AML stem/progenitor cells in combination with venetoclax can target intrinsic metabolic vulnerabilities and show distinct transcriptomic profiles, impacting the treatment of AML and other cancers with high AXL activity.

BLOOD (2021)

Add to Collection

Review Oncology

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach

Hagop M. Kantarjian et al.

Summary: Research on acute myeloid leukemia (AML) has progressed rapidly, with the US FDA approving 10 drugs for various AML indications since 2017. Different subsets of AML require tailored treatment strategies, including young patients fit for chemotherapy and older patients not suitable for intensive treatment, with combination therapy showing promising results.

CANCER (2021)

Add to Collection

Article Oncology

Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia

Caitlin R. Rausch et al.

Summary: Venetoclax combined with a hypomethylating agent has shown improved survival in elderly AML patients, but can lead to prolonged neutropenia and thrombocytopenia when combined with azole antifungals. Recovery times for neutrophils and platelets were similar in patients receiving azoles, but significantly longer for platelet recovery. Posaconazole and voriconazole did not significantly impact recovery times, suggesting safety of these combinations during treatment.

CANCER (2021)

Add to Collection

Article Oncology

A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia

Gautam Borthakur et al.

Summary: The study investigated the safety and efficacy of the pan-BET inhibitor mivebresib as monotherapy and in combination with venetoclax in patients with relapsed/refractory AML. Adverse effects of the drug were dose-dependent, and some patients showed improvement in their leukemia. Further studies are needed to determine the potential of mivebresib in treating acute myeloid leukemia.

CANCER (2021)

Add to Collection

Review Oncology

New Treatment Options for Older Patients with Acute Myeloid Leukemia

Kapil Saxena et al.

Summary: The treatment of acute myeloid leukemia (AML) has advanced significantly in recent years, with a growing understanding of the molecular basis of leukemogenesis leading to the introduction of targeted agents for patients of all ages. Current approaches for elderly AML patients involve a backbone regimen of hypomethylating agents or low-intensity chemotherapy with targeted inhibitors, with the option of a doublet/triplet strategy for patients with targetable mutations.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies

Carmelo Gurnari et al.

Summary: Research on metabolic deregulation in myeloid malignancies has shown that cells undergoing leukemic transformation have higher energy demands for growth and proliferation, leading to a focus on metabolic-targeted therapies. However, the most difficult challenge is determining a therapeutic window that selectively impacts malignant cells without harming normal cells. It has been found that leukemic cells have unique metabolic features, such as IDH1/2 mutations leading to abnormal metabolite production inhibiting enzyme activity.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine

Ralf Buettner et al.

Summary: The combination of 8-Cl-Ado and VEN synergistically inhibits the in vitro growth of AML cells and prolongs survival in a mouse model, possibly by targeting FAO and OXPHOS pathways. This combination represents a promising therapeutic regimen for AML treatment.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Review Medicine, General & Internal

Acute myeloid leukaemia in patients we judge as being older and/or unfit

V. Lj. Lazarevic

Summary: The definition of older age in AML is arbitrary, with various age thresholds used in clinical studies. Treatment decisions for older AML patients should be personalized and shared through dialogue with patients and their families. Despite advances in research and therapy, curing older patients with AML remains a challenge.

JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Health Care Sciences & Services

Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia

Gabriel Tremblay et al.

Summary: The study found that there were no significant differences in efficacy between glasdegib+LDAC and venetoclax+LDAC in treating acute myeloid leukemia patients unfit for intensive chemotherapy. Therefore, considerations such as safety profiles, burden of administration, and patient preference are important factors in guiding treatment decisions.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)

Add to Collection

Article Medicine, General & Internal

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience

Matteo Piccini et al.

Summary: For patients with relapsed/refractory acute myeloid leukemia, venetoclax-based regimens show promise in achieving composite complete response rates, with particular benefit seen in patients with NPM1 mutations. The possibility of undergoing transplant in intention-to-treat patients was 54%.

JOURNAL OF CLINICAL MEDICINE (2021)

Add to Collection

Letter Oncology

Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia

Xiang Zhang et al.

Summary: The study found that the mechanism of acquired VEN resistance in AML patients differs from CLL, where reconstructed existing gene mutations mainly contribute to VEN resistance. Precise mutation monitoring and targeted therapy may be effective strategies to prevent and overcome acquired VEN resistance in AML.

BIOMARKER RESEARCH (2021)

Add to Collection

Article Hematology

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Abhishek Maiti et al.

Summary: Assessment of measurable residual disease (MRD) provides prognostic information in acute myeloid leukemia (AML). However, it remains unclear how MRD status impacts survival outcomes in older/unfit patients receiving first-line therapy with 10-day decitabine and venetoclax. This study found that achieving a negative MRD at 1, 2, and 4 months post-treatment significantly improved survival in this patient population.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Lucia Masarova et al.

Summary: In patients with acute myeloid leukemia evolving from myeloproliferative neoplasms, the clinical activity of the B-cell lymphoma 2 inhibitor venetoclax remains to be determined. Venetoclax-based regimens showed modest short-lived responses in newly diagnosed patients, while no formal responses were seen in relapsed/refractory patients. However, significant treatment-associated hematologic toxicity and mortality were observed, highlighting the urgent need for additional treatment options for these patients.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Curtis A. Lachowiez et al.

Summary: This study compared outcomes in patients with spliceosome mutations vs wild-type patients treated with HMA+VEN regimens, revealing comparable responses and overall survival. Specific co-mutations, such as IDH2 and RAS, were found to impact outcomes in these patients.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Jonathan Feld et al.

Summary: The combination of HMA and venetoclax in patients with AML and myelodysplastic syndrome shows impressive response rates and moderately durable remissions and survival. However, the benefits may be limited by significant toxicities such as infection, persistent cytopenias, and transfusion requirements.

HEMASPHERE (2021)

Add to Collection

Article Oncology

Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia

Caitlin R. Rausch et al.

Summary: Background: Venetoclax combined with HMA improves survival in elderly patients with AML. However, this treatment can lead to profound neutropenia, requiring antifungal prophylaxis. Limited data exist on the outcomes of patients receiving VEN, HMA, and azoles.

CANCER (2021)

Add to Collection

Article Oncology

BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia

Haley E. Ramsey et al.

Summary: The study shows that the novel BET inhibitor INCB054329 in combination with venetoclax can reduce AML burden without inducing toxicity, suggesting a potentially more efficacious treatment option for patients with AML.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Hematology

Venetoclax-containing regimens in acute myeloid leukemia

Ibrahim Aldoss et al.

Summary: The combination of Venetoclax with hypomethylating agents or low-dose cytarabine has shown exceptional activity in elderly and unfit patients with newly diagnosed AML. The safety profile of Venetoclax-based regimens is favorable, even in frail participants, transforming the landscape of AML therapy in elderly patients. Ongoing studies are investigating the use of Venetoclax in frontline therapy for younger patients as well as in relapsed/refractory AML patients.

THERAPEUTIC ADVANCES IN HEMATOLOGY (2021)

Add to Collection

Article Hematology

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study

Daniel A. Pollyea et al.

Summary: This study provides the longest-term follow-up analysis for AML patients treated with venetoclax plus azacitidine or decitabine. The results indicate that venetoclax plus hypomethylating agents are highly effective frontline therapies for AML patients unfit for intensive chemotherapy.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types

Muntasir M. Majumder et al.

HAEMATOLOGICA (2020)

Add to Collection

Article Oncology

AML: New Drugs but New Challenges

Alan Burnett et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)

Add to Collection

Article Oncology

Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia

Christopher A. Eide et al.

LEUKEMIA (2020)

Add to Collection

Article Oncology

Venetoclax in acute myeloid leukemia - current and future directions

Curtis Lachowiez et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection

Article Oncology

Oral adherence in adults with acute myeloid leukemia (AML): results of a mixed methods study

Ashley Leak Bryant et al.

SUPPORTIVE CARE IN CANCER (2020)

Add to Collection

Article Hematology

The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia

Michael Byrne et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Hematology

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei et al.

BLOOD (2020)

Add to Collection

Article Oncology

Venetoclax is safe and efficacious in relapsed/refractory AML

Chezi Ganzel et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection

Article Oncology

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia

Xiangmeng Wang et al.

MOLECULAR CANCER THERAPEUTICS (2020)

Add to Collection

Article Cell Biology

Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity

Ida Sofie Gronningsaeter et al.

CELLS (2020)

Add to Collection

Article Hematology

Venetoclax and hypomethylating agents inFLT3-mutated acute myeloid leukemia

Ibrahim Aldoss et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Review Hematology

Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Juan Eduardo Megias-Vericat et al.

ANNALS OF HEMATOLOGY (2020)

Add to Collection

Review Oncology

Treatment of Relapsed Acute Myeloid Leukemia

Felicitas Thol et al.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)

Add to Collection

Article Hematology

Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML

Myriam Hormi et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Review Genetics & Heredity

AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances

Kristin L. Koenig et al.

GENES (2020)

Add to Collection

Article Oncology

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Chong Chyn Chua et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients

Erika Morsia et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Hematology

Acute myeloid leukemia: 2021 update on risk-stratification and management

Elihu H. Estey

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Oncology

Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition

Mahesh Tambe et al.

LEUKEMIA (2020)

Add to Collection

Article Oncology

Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience

Armon Azizi et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection

Article Oncology

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine

Rie Nishi et al.

BMC CANCER (2020)

Add to Collection

Article Oncology

Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner

Shujuan Huang et al.

MOLECULAR ONCOLOGY (2020)

Add to Collection

Article Cell & Tissue Engineering

Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells

Courtney L. Jones et al.

CELL STEM CELL (2020)

Add to Collection

Article Medicine, General & Internal

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

C. D. DiNardo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Srividya B. Balachander et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Hematology

Venetoclax in AML: Where We Are and Where We Are Headed

Daniel A. Pollyea

Clinical Lymphoma Myeloma & Leukemia (2020)

Add to Collection

Review Oncology

A precision medicine approach to management of acute myeloid leukemia in older adults

Shristi Upadhyay Banskota et al.

CURRENT OPINION IN ONCOLOGY (2020)

Add to Collection

Article Cell Biology

Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway

Yuan-Fei Shi et al.

CELL DEATH & DISEASE (2020)

Add to Collection

Review Oncology

Management of Acute Myeloid Leukemia (AML) in Older Patients

Maya Abdallah et al.

CURRENT ONCOLOGY REPORTS (2020)

Add to Collection

Article Cell Biology

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia

Kai Chen et al.

CELL DEATH & DISEASE (2020)

Add to Collection

Article Hematology

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo et al.

LANCET HAEMATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics

Inke De haes et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Oncology

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Shruti Bhatt et al.

CANCER CELL (2020)

Add to Collection

Review Hematology

Apoptosis targeted therapies in acute myeloid leukemia: an update

Somedeb Ball et al.

EXPERT REVIEW OF HEMATOLOGY (2020)

Add to Collection

Article Education, Scientific Disciplines

Therapeutic development and current uses of BCL-2 inhibition

Andrew W. Roberts

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)

Add to Collection

Article Education, Scientific Disciplines

Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?

Evan C. Chen et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)

Add to Collection

Review Pharmacology & Pharmacy

Novel therapies for AML: a round-up for clinicians

Mahesh Swaminathan et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia

Cristina Bilbao-Sieyro et al.

DIAGNOSTICS (2020)

Add to Collection

Letter Oncology

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML

JingHan Wang et al.

BIOMARKER RESEARCH (2020)

Add to Collection

Article Hematology

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short et al.

BLOOD ADVANCES (2020)

Add to Collection

Review Oncology

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia

Yunxiong Wei et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Review Oncology

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points

Naseema Gangat et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Review Hematology

The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis

Bei Liu et al.

HEMATOLOGY (2020)

Add to Collection

Review Oncology

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions

Bachar Samra et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells

Brett M. Stevens et al.

NATURE CANCER (2020)

Add to Collection

Review Oncology

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Naval Daver et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Review Cell Biology

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance

Isha Kapoor et al.

CELL DEATH & DISEASE (2020)

Add to Collection

Review Oncology

B-cell lymphoma-2 inhibition and resistance in acute myeloid leukemia

Lindsay Wilde et al.

WORLD JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Review Oncology

The Time Has Come for Targeted Therapies for AML: Lights and Shadows

Alessandro Fiorentini et al.

ONCOLOGY AND THERAPY (2020)

Add to Collection

Article Oncology

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

Haijiao Zhang et al.

NATURE CANCER (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Dietrich A. Ruess et al.

NATURE MEDICINE (2018)

Add to Collection

© Peeref 2019-2024. All rights reserved.